Dennis Burton, PhD

Lab Info:

Principal Investigator: Dennis Burton, PhD

Office/Location: Scripps, CA

Phone: (858) 784-9298

Email: burton@scripps.edu

Category: Steering Committee

Dennis Burton is Professor of Immunology and Microbiology at the Scripps Research Institute in La Jolla, California; Member of the Steering Committee of the Ragon Institute of MGH, MIT and Harvard; Scientific Director of the Neutralizing Antibody Consortium of the International AIDS Vaccine Initiative and Director of the NIH Center for HIV/AIDS Vaccine Immunology and Immunogen Discovery at The Scripps Research Institute. He received a B.A. degree in Chemistry from the University of Oxford and a Ph.D. degree in nuclear magnetic resonance in biology from the University of Lund, Sweden. His early work focused on understanding antibody effector function and he was one of the co-discoverers of the complement and Fc receptor binding sites on immunoglobulin G.


At Scripps, Burton described the first recombinant antibodies isolated from phage libraries in the laboratory of Richard Lerner. In his own laboratory, he pioneered the isolation of human antibodies from immune donors, most notably from a variety of viral infections including HIV, HCV, RSV and Ebola virus. For HIV, he defined many of the anti-viral activities of human antibodies in vitro and in vivo. He also helped describe the structural basis for neutralization by several prototype broadly neutralizing antibodies together with Ian Wilson. He was an early champion of the rational vaccine design approach to highly variable and difficult pathogens such as HIV, HCV and influenza virus. More recently, Burton has been at the forefront of generating novel highly potent broadly neutralizing antibodies to HIV that are re-invigorating the attempts to design an HIV vaccine via rational structure-based strategies.


He is a Fellow of the American Academy of Microbiology, was a Jenner Fellow of the Lister Institute of Preventive Medicine, has received two NIH Merit awards and has given several named lectures including the Bernard Fields Lecture of the Conference on Retroviruses and Opportunistic Infections (CROI).


Laboratory Website


Research Areas

Antibodies and Infectious Disease: The perception of man as the easy victor over microbes has changed dramatically in the last two decades. Vaccination has offered protection against a number of viral pathogens, but it is increasingly recognized that the strategies used in the past will not be successful against all viruses. More understanding of viral pathogenesis and the interaction of viruses with the immune system is required. We are focused on the interplay of antibodies and viruses in humans, and it particular, the highly mutable viruses, human immunodeficiency virus type 1 (HIV-1) and hepatitis C virus (HCV). We have developed broadly neutralizing antibodies to these viruses to explore the anti-viral activity of antibodies in vitro and in vivo and to define molecular targets for rational vaccine design.

Selected Publications

Burton DR, Hyde JE and Walker IO. Histones F2al and F3 interact reversibly and cooperatively with DNA to form an equimolar complex in chromatin. FEBS (Letts), 55:77-80, 1975.


Burton DR, Dwek RA, Forsén S and Karlstrom G. A novel approach to water proton relaxation in paramagnetic ion macromolecule complexes. Biochemistry, 16:250-254, 1977.


Burton DR, Boyd J, Brampton AD, Easterbrook-Smith S, Emanuel EJ, Novotny J, Rademacher TW, van Schravendijk MR, Sternberg MJE and Dwek RA. The C1q receptor site on immunoglobulin G. Nature, 288:338-344, 1980.


Burton DR, Forsén S and Reimarsson P. The interaction of polyamines and DNA studied by 23Na NMR. Nucl. Acid. Res., 9:1219-1228, 1981.


Woof JM, Nik Jaafar MI, Jefferis R, and Burton DR. The monocyte binding domain(s) on human immunoglobulin G. Molec. Immun., 21:523-527, 1984.


Woof JM, Partridge LJ, Jefferis R and Burton DR. Localisation of the monocyte binding region on human immunoglobulin G. Molec. Immunol., 23:319-330, 1986.


Burton DR. Is IgM-like dislocation a common feature of antibody function? Immunol. Today, 7:165-167, 1986.


Gregory L, Davis KG, Sheth B, Boyd J, Jefferson R, Nave C and Burton DR. The solution conformations of the subclasses of human IgG deduced from sedimentation and small-angle X-ray scattering. Molec. Immunol., 24:821-829, 1987.


Duncan AR, Woof JM, Partridge LJ, Burton DR and Winter G. Localization of the binding site for the human high affinity Fc receptor on IgG. Nature, 332: 563-564, 1988.


Huse WD, Sastry L, Iverson SA, Kang AS, Alting-Mees M, Burton DR, Benkovic SJ and Lerner RA. Generation of a large combinatorial library of the immunoglobulin repertoire in phage lambda. Science, 246:1275-1281, 1989.


Persson MAA, Caothien RH and Burton DR. Generation of diverse high-affinity human monoclonal antibodies by repertoire cloning. Proc. Natl. Acad. Sci. USA, 88:2432-2436, 1991.


Kang AS, Jones TM and Burton DR. Antibody redesign by chain shuffling from random combinatorial immunoglobulin libraries. Proc. Natl. Acad. Sci. USA, 88:11120-11123, 1991.


Burton DR, Barbas CF 3rd,  Persson MAA, Koenig S, Chanock RM and Lerner RA. A large array of human monoclonal antibodies to HIV-1 from combinatorial libraries of asymptomatic seropositive individuals. Proc. Natl. Acad. Sci. USA, 88:10134-10137, 1991.


Duchosal MA, Eming SA, Fischer P, Leturcq D, McConahey PJ, Caothien RH, Barbas CF 3rd, Thornton GB, Dixon FJ and Burton DR. Immunization of hu-PBL-SCID mice and the rescue of human monoclonal Fab fragments via combinatorial libraries. Nature, 355:258-262, 1992.


Barbas CF 3rd, Björling E, Chiodi F, Dunlop N, Cababa D, Jones TM, Zebedee SL, Persson MAA, Nara PL, Norrby E and Burton DR. Recombinant human Fab fragments neutralize human type 1 immunodeficiency virus in vitro. Proc. Natl. Acad. Sci. USA, 89:9339-9343, 1992.


Barbas CF 3rd, Crowe JE Jr., Cababa D, Jones TM, Zebedee SL, Murphy BR, Chanock RM and Burton DR. Human monoclonal Fab fragments derived from a combinatorial library bind to respiratory syncytial virus F glycoprotein and neutralize infectivity. Proc. Natl. Acad. Sci. USA, 89:10164-10168, 1992.


Barbas CF 3rd, Collett TA, Amberg W, Roben P, Binley JM, Hoekstra D, Cababa D, Jones TM, Williamson RA, Pilkington GR, Haigwood NL, Satterthwait AC, Sanz I and Burton DR. Molecular profile of an antibody response to HIV-1 as probed by combinatorial libraries. J. Mol. Biol., 230:812-823, 1993.


Williamson RA, Burioni R, Sanna P, Partridge L, Barbas CF 3rd and Burton DR. Human monoclonal antibodies against a plethora of viral pathogens from single combinatorial libraries. Proc. Natl. Acad. Sci. USA, 90:4141-4145, 1993.


Burioni R, Williamson RA, Sanna PP, Bloom FE and Burton DR. Recombinant human Fab to glycoprotein D neutralizes infectivity and prevents cell-to-cell transmission of herpes simplex virus type-1 and -2 in vitro. Proc. Natl. Acad. Sci. USA, 91:355-359, 1994.


Crowe JE Jr, Murphy BR, Chanock RM, Williamson RA, Barbas CF 3rd and Burton DR. Recombinant human RSV monoclonal antibody Fab is effective therapeutically when introduced directly into the lungs of respiratory syncytial virus-infected mice. Proc. Natl. Acad. Sci. USA, 91:1386-1390, 1994.


Barbas SM, Ghazal P, Barbas CF 3rd and Burton DR. Recognition of DNA by synthetic antibodies. J. Am. Chem. Soc., 116:2161-2162, 1994.


Ditzel HJ, Barbas SM, Barbas CF 3rd and Burton DR. The nature of the autoimmune antibody repertoire in human immunodeficiency virus type 1 infection. Proc. Natl. Acad. Sci USA, 91:3710-3714, 1994.


Barbas CF 3rd, Hu D, Dunlop N, Sawyer L, Cababa D, Hendry RM, Nara PL and Burton DR. In vitro evolution of a neutralizing human antibody to human immunodeficiency virus type 1 to enhance affinity and broaden strain cross-reactivity. Proc. Natl. Acad. Sci. USA, 91:3809-3813, 1994.


Roben P, Moore JP, Thali M, Sodroski J, Barbas CF 3rd, and Burton DR. Recognition properties of a panel of human recombinant Fab fragments to the CD4 binding site of gp120 showing differing ability to neutralize human immunodeficiency virus type 1. J. Virol. 68:4821-4828, 1994.


Hexham JM, Partridge LJ, Furmaniak J, Petersen VB, Colls JC, Pegg CAS, Smith BR and Burton DR. Cloning and characterization of TPO autoantibodies using combinatorial phage display libraries. Autoimmunity, 17:167-179, 1994.


Burton, DR*, Pyati J, Koduri R , Sharp SJ, Thornton GB, Parren PWHI, Sawyer LSW, Hendry RM, Dunlop N, Nara PL, Lamacchia M, Garratty E, Stiehm ER, Bryson YJ, Cao Y, JMoore JP, Ho DD and Barbas CF 3rd*. Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody. Science, 266:1024-1027, 1994.


Barbas SM, Ditzel HJ, Salonen EM, Yang WP, Silverman GJ and Burton DR. Human autoantibody recognition of DNA. Proc. Natl. Acad. Sci. USA, 92: 2529-2533, 1995.


Parren PWHI, Ditzel HJ, Gulizia RJ, Binley JM, Barbas CF 3rd, Burton DR* and Mosier DE. Protection against HIV-1 infection in hu-PBL-SCID mice by passive immunization with a neutralizing human monoclonal antibody against the gp120 CD4-binding site. AIDS, 9:F1-F6, 1995.


Sanna PP, Williamson RA, De Logu A, Bloom FE and Burton DR. Directed selection of recombinant human monoclonal antibodies to HSV glycoproteins from phage display libraries. Proc. Natl. Acad. Sci. USA, 92:6439-6443, 1995.


Yang W-P, Green K, Pinz-Sweeney S, Briones AT, Burton DR and Barbas CF 3rd. CDR walking mutagenesis for the affinity maturation of a potent human anti-HIV-1 antibody into the picomolar range. J. Mol. Biol., 254:392-403, 1995.


Sanna PP, De Logu A, Williamson RA, Hom Y-L, Straus SE, Bloom FE and Burton DR. Protection of nude mice by passive immunization with a type-common human recombinant monoclonal antibody against HSV. Virology, 215:101-106, 1996.


Williamson RA, Peretz D, Smorodinsky N, Bastidas R, Blochberger T, Serban A, DeArmond S, Prusiner SB and Burton DR. Circumventing tolerance in order to generate autologous monoclonal antibodies to the prion protein. Proc. Natl. Acad. Sci. USA, 93:7279-7282, 1996.


Ditzel HJ, Parren PWHI, Binley JM, Sodroski J, Moore JP, Barbas CF 3rd and Burton DR. Mapping the protein surface of HIV-1 gp120 using human monoclonal antibodies from phage display libraries. J. Mol. Biol. 267:684-695, 1997.


Graus YF, de Baets MH, Parren PWHI, Berrih-Aknin S, Wokke J, Van Breda Vriesman PJ and Burton DR. Human anti-nicotinic acetylcholine receptor recombinant Fab fragments isolated from thymus-derived phage display libraries from myasthenia gravis patients reflect predominant specificities in serum and block the action of pathogenic serum antibodies. J. Immunol. 158:1919-1929, 1997.


Peretz D, Williamson RA, Matsunaga Y, Serban H, Pinilla C, Bastidas RB, Rozenshteyn R, James TL, Houghten RA, Cohen FE, Prusiner SB and Burton DR. A conformational transition at the N-terminus of the prion protein features in formation of the scrapie isoform. J. Mol. Biol., 273:614-622, 1997.


Gauduin M-C, Parren PWHI, Weir R, Barbas CF 3rd, Burton DR* and R.A. Koup. Passive immunization with a human monoclonal antibody protects hu-PBL-SCID mice against challenge by primary isolates of HIV-1. Nat. Med., 3:1389-1393, 1997.


Parren PWHI, Mondor I, Naniche D, Ditzel HJ, Klasse P-J, Burton DR* and Sattentau QJ. Neutralization of HIV-1 by antibody to gp120 is determined primarily by occupancy of sites on the virion irrespective of epitope specificity. J. Virol., 72:3512-3519, 1998.


Williamson RA, Peretz D, Pinilla C, Ball H, Bastidas RB, Rozenshteyn R, Houghten RA, Prusiner SB and Burton DR. Mapping the prion protein using recombinant antibodies. J. Virol., 72: 9413-9418, 1998.


Maruyama T,  Parren PWHI, Sanchez A, Rensink I, Rodriguez LL, Khan AS, Peters CJ and Burton DR. Recombinant human monoclonal antibodies to Ebola virus. J. Infect. Dis., 179(Suppl 1):S235-9, 1999.


Sakurai H, Williamson RA, Crowe JE, Beeler JA, Poignard P, Bastidas RB, Chanock RM and Burton DR. Human antibody responses to mature and immature forms of viral envelope in RSV infection: significance for subunit vaccines. J. Virol., 73:2956-2962, 1999.


Poignard P, Sabbe R, Picchio GR, Wang M, Gulizia RJ, Katinger H, Parren PWHI, Mosier DE and Burton DR. Neutralizing antibodies have limited effects on the control of established HIV-1 infection in vivo. Immunity, 10: 431-438, 1999.


Maruyama T, Rodriguez LL, Jahrling PB, Sanchez A, Khan AS, Nichol ST, Peters CJ, Parren PWHI and Burton DR. Ebola virus can be effectively neutralized by antibody produced in natural human infection. J. Virol., 73:6024-6030, 1999.


Leclerc E, Peretz D, Ball H, Sakurai H, Legname G, Serban A, Prusiner SB, Burton DR* and Williamson RA*. Immobilized prion protein undergoes spontaneous rearrangement to a conformation having features in common with the infectious form. EMBO J., 20, 1547-1554, 2001.


Parren PWHI, Marx P, Hessell AJ, Luckay A, Harouse J, Cheng-Mayer C, Moore JP and Burton DR. Antibody protects macaques against vaginal challenge with a pathogenic R5 simian/human immunodeficiency virus at serum levels giving complete neutralization in vitro. J. Virol. 75:8340-8347, 2001.


Saphire EO, Parren PWHI, Pantophlet R, Zwick MB, Rudd P, Dwek R, Burton DR* and Wilson IA*. Crystal structure of an intact human IgG with potent and broad activity against primary HIV-1 isolates: A template for HIV vaccine design. Science, 293:1155-1159, 2001.


Peretz D, Williamson RA*, Kaneko K, Vergara J, Leclerc E, Mehlhorn IR, Legname G, Wormald MR, Rudd PM, Burton DR* and Prusiner SB. Antibodies abolish prion propagation and promote clearance of infectivity from cell culture. Nature, 412:739-743, 2001.


Zwick MB, Labrijn AF, Wang M, Spenlehauer C, Saphire EO, Binley JM, Moore JP, Stiegler G, Katinger H,  Burton DR* and Parren PWHI*. Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodeficiency virus type 1 glycoprotein gp41. J. Virol., 75: 10892-10905, 2001.


Parren PWHI, Geisbert TW, Maruyama T, Jahrling PB and Burton DR. Pre and Post-Exposure Prophylaxis of Ebola Virus Infection in an Animal Model by Passive Transfer of a Neutralizing Human Antibody. J. Virol., 76:6408-6412, 2002.


Scanlan CN, Pantophlet R, Wormald MR, Saphire EO, Stanfield R, Wilson IA, Katinger H, Dwek RA, Rudd PM* and Burton DR*. The broadly neutralizing anti-HIV-1 antibody 2G12 recognizes a cluster of a1®2 mannose residues on the outer face of GP120. J. Virol., 76:7306-7321, 2002.


Pantophlet R, Saphire EO, Poignard P, Parren PWHI, Wilson IA, and Burton DR. Fine mapping of the interaction of neutralizing and non-neutralizing monoclonal antibodies with the CD4 binding site of HIV-1 gp120, J. Virol., 77: 642-658, 2003.


Poignard* P, Moulard M, Golez E, Vivona V, Franti M, Venturini S, Wang M, Parren PWHI and Burton DR*. Heterogeneity of envelope molecules expressed on primary human immunodeficiency virus type 1 particles as probed by the binding of neutralizing and nonneutralizing antibodies. J. Virol., 77: 353-365, 2003.


Safar JG, Scott M, Monaghan J, Deering C, Didorenko S, Vergara J, Ball H, Legname G, Leclerc E, Solforosi L, Serban H, Groth D, Burton DR*, Prusiner SB* and Williamson RA. Measuring prions causing bovine spongiform encephalopathy or chronic wasting disease by immunoassays and transgenic mice. Nature Biotechnology, 20:1147-1150, 2002.


Veazey, RS, Shattock RJ, Pope M, Kirijan JC, Jones J, Hu Q, Ketas T, Marx PA, Klasse PJ, Burton DR and Moore JP. Prevention of virus transmission to macaque monkeys by a vaginally applied monoclonal antibody to HIV-1gp120. Nature Medicine, 9:343-346, 2003.


Pantophlet R, Wilson IA and Burton DR. Hyperglycosylated mutants of human immunodeficiency virus (HIV) type 1 monomeric gp120 as novel antigens for HIV vaccine design. J. Virol., 77:5889-5901, 2003.


Zwick MB, Parren PWHI, Saphire EO, Wang M, Scott JK, Dawson PE, Wilson IA and Burton DR. Molecular Features of the broadly neutralizing antibody b12 required for recognition of HIV-1 gp 120. J. Virol., 77:5863-5876, 2003.


Zwick MB, Kelleher R, Jensen R, Labrign AF, Wang M, Quinnan GV Jr., Parren PWHI and Burton DR. A novel human antibody against HIV-1 gp120 is V1, V2 and V3 loop-dependent and helps delimit the epitope of the broadly neutralizing antibody IgG1 b12. J. Virol., 77:6965-6978, 2003.


Binley JM, Cayanan CS, Wiley C, Schulke N, Olson WC and Burton DR. Redox-triggered Infection by disulfide-shackled HIV-1 pseudovirions. J. Virol., 77:5678-5684, 2003.


Calarese DA, Scanlan CN, Zwick MB, Deechongkit S, Mimura Y, Kunert R, Zhu P, Wormald MR, Stanfield RL, Roux KH, Kelly JW,  Rudd PM, Dwek RA, Katinger H, Burton DR* and Wilson IA*. Antibody domain exchange is an immunological solution to carbohydrate cluster recognition. Science, 300:2065-2071, 2003.


Labrijn AF, Poignard P, Raja A, Zwick MB, Delgado K, Franti M, Binley J, VVivona V, Grundner C, Huang C-C, Venturi M, Petropoulos CJ, Wrin T, Dimitrov DS, Robinson J, Kwong P, Wyatt RT, Sodroski J and Burton DR, Access of antibody molecules to the conserved coreceptor binding site on glycoprotein g120 is sterically restricted on primary HIV-1. J. Virol., 77: 10557-10565, 2003.


Lee HK, Scanlan CN, Huang C-Y, Chang AY, Calarese DA, Dwek RA, Rudd PM, Burton DR, Wilson IA and Wong C-H. Reactivity based one-pot synthesis of oligomannoses: Defining antigens recognized by 2G12, a broadly neutralizing antibody of HIV-1. Angewandte Chemie, 43:1000-1003, 2004.


Zwick MB, Komori HK, Stanfield RL, Church S, Wang M, Parren PWHI, Kunert R,Katinger H, Wilson IA and Burton DR. The long third complementarity-determining region of the heavy chain is important in the activity of the broadly neutralizing anti-HIV-1 antibody 2F5. J. Virol., 78:3155-3161, 2004.


Moroncini G, Kanu N, Solforosi L, Abalos G, Telling GC, Head M, Ironside J, Brochs JP, Burton DR* and Williamson RA*. Motif-grafted antibodies containing the replicative interface of cellular PrP are specific for PrPSc. Proc. Natl. Acad. Sci. USA, 101:10404-10409, 2004.


Binley JM, Wrin T, Korber B, Zwick MB, Wang M, Chappey C, Stiegler G, Kunert R, Zolla-Pazner S, Katinger H, Petropoulos CJ and Burton DR. A comprehensive cross-clade neutralization analysis of panel of anti-HIV-1 monoclonal antibodies. J. Virol., 78:13232-13252, 2004.


Pantophlet R, Wilson I and Burton DR. Improved design of an antigen with enhanced specificity for the broadly HIV-neutralizing antibody b12. Protein Engineering, Design and Selection, 17:749-758, 2004.


Zwick MB, Jensen R, Church S, Wang M, Stiegler G, Kunert R, Katinger H and Burton DR. The anti-human immunodeficiency virus type 1 antibodies 2F5 and 4E10 require only a surprisingly few crucial residues in the membrane-proximal external region of glycoprotein gp41 to neutralize HIV-1. J. Virol., 79:1252-1261, 2005.


Cardoso RMF, Zwick MB, Stanfield RL, Kunert R, Binley JM, Katinger H, Burton DR* and Wilson IA*. Broadly neutralizing anti-HIV antibody 4E10 recognizes a helical conformation of a highly conserved fusion-associated motif in gp41: Implications for vaccine design. Immunity, 22:163-173, 2005.


Selvarajah S, Puffer B, Pantophlet R, Law M, Doms RW and Burton DR. Comparing antigenicity and immunogenicity of engineered gp120. J. Virol., 79:12148-12163, 2005.


Luginbuhl, B, Kanyo Z, Jones RM, Fletterick RJ, Prusiner SB, Cohen FE, Williamson RA, D.R. Burton DR, Pluckthun A. Directed evolution of an anti-prion scFv fragment to an affinity of 1 pM and its structural interpretation, J. Mol. Biol., 363:75-97, 2006.


Oswald WB, Geisbert TW, Davis KJ, Geisbert JB, Sullivan NJ, Jahrling PB, Parren PWHI, Burton DR. Neutralizing antibody fails to impact the course of Ebola virus infection in monkeys, PLoS Pathogens, 3:62-66 2007.


Bowley DR, Labrijn AF, Zwick MB, Burton DR. Antigen selection from an HIV-1 immune antibody library displayed on yeast yields many novel antibodies compared to selection from the same library displayed on phage, Protein Engineering Design & Selection (PEDS), 20:81-90, 2007.


Hessell AJ, Hangartner L, Hunter M, Havenith CE, Beurskens FJ, Bakker JM, Lanigan CM, Landucci G, Forthal DN, Parren PW, Marx PA, Burton DR. Fc receptor but not complement binding is important in antibody protection against HIV. Nature 2007 Sep 6;449(7158):101-4. PMID: 17805298.


Law M, Cardoso RMF, Wilson IA, Burton DR. Antigenic and immunogenic study of membrane-proximal external region-grafted gp120 antigens by a DNA prime-protein boost immunization strategy. J. Virol., 81: 4272-4285, 2007.


Dhillon AK, Donners H, Pantophlet R, Johnson WE, Decker JM, Shaw GM, Lee F-H, Richman DD, Doms RW, Vanham G, Burton DR. Dissecting the neutralizing antibody specificities of broadly neutralizing sera from HIV-1 infected donors. J. Virol., 81:6548-6562, 2007.


Scherer EM, Zwick MB, Teyton L, Burton DR. Difficulties in eliciting broadly neutralizing anti-HIV antibodies are not explained by cardiolipin autoreactivity. AIDS, 21:2131-2139, 2007.


Law M, Maruyama T, Lewis J, Giang E, Tarr AW, Stamataki Z, Gastaminza P, Chisari FV, Jones IM, Fox RI, Ball JK, McKeating JA, Kneteman NM, Burton DR. Broadly neutralizing antibodies protect against hepatitis C virus quasispecies challenge. Nature Medicine. 2008 Jan;14(1):25-7. PMID: 18064037.


Walker BD, Burton DR. Toward an AIDS vaccine. Science 2008 May 9;320(5877):760-4. PMID: 18467582.


Wang S-K, Liang P-H, Astronomo RD, Hsu T-L, Hsieh S-L, Burton DR, Wong C-H. Targeting the carbohydrates on HIV-1: interaction of oligomannose dendrons with human monoclonal antibody 2G12 and DC-SIGN. Proc. Natl. Acad. Sci. USA, 105:3690-3695, 2008. PMCID: PMC2268808.


Astronomo RD, Lee H-K , Scanlan CN, Pantophlet R, Huang C-Y, Wilson IA, Blixt O, Dwek RA, Wong C-H, Burton DR. A glycoconjugate antigen, based on the recognition motif of a broadly-neutralizing HIV antibody, 2G12, is immunogenic but elicits antibodies unable to bind to the ‘self’ glycans of gp120. J. Virol., 82:6359-6368, 2008. PMCID: PMC2447108.


Nicolaou, KC, Wu TR, Sarlah D, Shaw DM, Rowcliffe E, Burton DR. Total synthesis, revised structure, and biological evaluation of biyouyanagin A and analogues thereof. J. Am. Chem. Soc., 130:11114-11121, 2008. PMCID: PMC 2614900.


Pantophlet R, Wrin T, Cavacini LA, Robinson JE, Burton DR. Neutralizing activity of antibodies to the V3 loop region of HIV-1 gp120 relative to their epitope fine specificity. Virol., 38:251-60, 2008. PMCID: PMC2613967.


Hessell AJ, Rakasz EG, Poignard P, Hangartner L, Landucci G, Forthal DN, Koff WC, Watkins DI, Burton DR. Broadly neutralizing human anti-HIV antibody 2G12 is effective in protection against mucosal SHIV challenge even at low serum neutralizing titers. PLoS Pathog. 2009 May; 5(5):e1000433. PMCID: PMC2674935.


Bowley DR, Jones TM, Burton DR, Lerner RA. Libraries against libraries for combinatorial selection of replicating antigen-antibody pairs. Proc Natl Acad Sci U S A., 106:1380-1385, 2009. PMCID: PMC2621251.


Pantophlet R, Wang M, Aguilar-Sino RO, Burton DR. The human immunodeficiency virus type 1 envelope spike of primary viruses can suppress antibody access to variable regions. J. Virol. 83:1649-1659, 2009. PMCID: PMC 2643787.


Hessell AJ, Hangartner L, Hunter M, Tehrani DM, Bleeker WK, Poignard P, Parren PWHI, Marx PA, Burton DR. Effective, low titer, antibody protection against low-dose repeated mucosal SHIV challenge in macaques. Nat. Med. 15:951-954, 2009.


Walker L, Bowley M, Burton DR. Efficient recovery of high affinity antibodies from a single chain Fab yeast display library. J. Mol. Biol. 389:365-375,2009.


Simek MD, Rida W, Priddy FH, Pung P, Carrow E, Laufer DS, Lehrman JK, Boaz M, Tarragona-Fiol T, Miiro G, Birungi J, Pozniak A, McPhee DA, Manigart O, Karita E, Inwoley A, Jaoko W, Dehovitz J, Bekker LG, Pitisuttithum P, Paris R, Walker LM, Poignard P, Wrin T, Fast PE, Burton DR, Koff WC. Human immunodeficiency virus type 1 elite neutralizers: individuals with broad and potent neutralizing activity identified by using a high-throughput neutralization assay together with an analytical selection algorithm. J Virol. 83:7337-7348, 2009. PMCID: PMC2704778.


Walker LM, Phogat SK, Chan-Hui PY, Wagner D, Phung P, Goss JL, Wrin T, Simek MD, Fling S, Mitcham JL, Lehrman JK, Priddy FH, Olsen OA, Frey SM, Hammond PW; Protocol G Principal Investigators, Miiro G, Serwanga J, Pozniak A, McPhee D, Manigart O, Mwananyanda L, Karita E, Inwoley A, Jaoko W, Dehovitz J, Bekker LG, Pitisuttithum P, Paris R, Allen S, Kaminsky S, Zamb T, Moyle ., Koff WC, Poignard P, Burton DR. Broad and Potent Neutralizing Antibodies from an African Donor Reveal a New HIV-1 Vaccine Target. Science, 326:285-9, 2009.PMCID: PMC2862588.


Scherer EM, Leaman DP, Zwick MB, McMichael AJ, Burton DR. Aromatic residues at the edge of the antibody combining site facilitate viral glycoprotein recognition through membrane interactions. Proc Natl Acad Sci U S A. 107:1529-34, 2010. PMCID: PMC2824387.


Hessell AJ, Rakasz EG, Tehrani DM, Huber M, Landucci G, Forthal DN, Koff WC, Poignard P, Watkins DI, and Burton DR. Broadly Neutralizing Monoclonal Antibodies 2F5 and 4E10, Directed Against the Human Immunodeficiency Virus Type 1 (HIV-1) gp41 Membrane Proximal External Region (MPER), Protect Against SHIVBa-L Mucosal Challenge. J. Virol., 84:1302-13, 2010.PMCID: PMC281233.


Astronomo, RD, Kaltgrad E, Udit AK, Wang S-K, Doores KJ, Huang C-Y, Pantophlet R, Paulson JC, Wong C-H, Finn MG, and Burton DR. Defining Criteria for Oligomannose Immunogens for HIV Using Icosahedral Virus Capsid Scaffolds. Chemistry & Biology 17: 357–370, 2010. PMCID: PMC2867452


Doores K J, Fulton Z, Huber M, Wilson IA, Burton DR. Antibody 2G12 recognizes di-mannose equivalently in domain- and nondomain-exchanged forms but only binds the HIV-1 glycan shield if domain exchanged. J Virol 84:10690-10699, 2010. PMCID: PMC2950587


Doores K J, Burton DR. Variable loop glycan dependency of the broad and potent HIV-1-neutralizing antibodies PG9 and PG16. J Virol 84:10510-10521, 2010. PMCID: PMC2950566.


Huber M, Le KM, Doores KJ, Fulton Z, Stanfield RL, Wilson IA, Burton DR. Very few substitutions in a germ line antibody are required to initiate significant domain exchange. J Virol 84:10700-10707, 2010. PMCID: PMC2950590.


Doores KJ, Bonomelli C, Harvey DJ, Vasiljevic S, Dwek RA, Burton DR, Crispin M, Scanlan CN. Envelope glycans of immunodeficiency virions are almost entirely oligomannose antigens. Proc Natl Acad Sci U S A 107:13800-5, 2010. PMCID: PMC2922250.


Pejchal R, Walker LM, Stanfield RL, Phogat SK, Koff WC, Poignard P, Burton DR, Wilson IA. Structure and function of broadly reactive antibody PG16 reveal an H3 subdomain that mediates potent neutralization of HIV-1. Proc Natl Acad Sci U S A 107:11483-8, 2010. PMCID: PMC2895122.


Walker LM, Simek MD, Priddy F, JGach JS, Wagner D, Zwick MB, Phogat SK, Poignard P, Burton DR. A limited number of antibody specificities mediate broad and potent serum neutralization in selected HIV-1 infected individuals. PLoS Pathog 6 pii: e1001028, 2010. PMCID: PMC2614900.


Weinfurter JT, May GE, Soma T, Hessell AJ, León EJ, Mac Nair CE, Piaskowski SM, Weisgrau K, Furlott J, Maness NJ, Reed J, Wilson NA, Rakasz EG, Burton DR, Friedrich TC. Macaque long-term nonprogressors resist superinfection with multiple CD8+ T cell escape variants of simian immunodeficiency virus. J Virol 2010 85:530-41. PMCID: PMC3014170.


Ng CT, Jaworski JP, Jayaraman P, Sutton WF, Delio P, Kuller L, Anderson D, Landucci G, Richardson BA, Burton DR, Forthal DN, Haigwood NL. Passive neutralizing antibody controls SHIV viremia and enhances B cell responses in infant macaques. Nat Med 16:1117-9, 2010. PMCID: PMC2952052.


Gavrilyuk J, Uehara H, Otsubo N, Hessell A, Burton DR, Barbas 3rd CF. Potent inhibition of HIV-1 entry with a chemically programmed antibody aided by an efficient organocatalytic synthesis. Chembiochem 11:2113-8, 2010.


Ackerman ME, Moldt B, Wyatt RT, Dugast AS, McAndrew E, Tsoukas S, Jost S, Berger CT, Sciaranghella G, Liu Q, Irvine DJ, Burton DR, Alter G. A robust, high-throughput assay to determine the phagocytic activity of clinical antibody samples. J Immunol Methods. 2010 7;366:8-19. PMCID: PMC3050993.


Doores KJ, Fulton Z, Hong V, Patel MK, Scanlan CN, Wormald MR, Finn MG, Burton DR, Wilson IA, Davis BG. A nonself sugar mimic of the HIV glycan shield shows enhanced antigenicity. Proc Natl Acad Sci. 2010 107:17107-12. PMCID: PMC2951454.


Shedlock DJ, Bailey MA, Popernack PM, Cunningham JM, Burton DR, Sullivan NJ. Antibody-mediated neutralization of Ebola virus can occur by two distinct mechanisms. Virology. 2010 401:228-35. PMCID PMC3351102.


Nicolaou KC, Sanchini S, Sarlah D, Lu G, Wu TR, Nomura DK, Cravatt BF, Cubitt B , de la Torre JC, Hessell AJ, Burton DR. Organic Synthesis Toward Small-Molecule Probes and Drugs Special Feature: Design, synthesis, and biological evaluation of a biyouyanagin compound library. Proc Natl Acad Sci. 2011 108:6715-20. PMCID: PMC3084107.


Chakrabarti BK, Walker LM, Guenaga JF, Ghobbeh A, Poignard P, Burton DR, Wyatt RT. Direct antibody access to the HIV-1 membrane-proximal external region positively correlates with neutralization sensitivity. J Virol. 2011 85:8217-26. PMCID: PMC3147955.


Dorner M, Horwitz JA, JRobbins JB, Barry WT, Feng Q, Mu K, Jones CT, Schoggins JW, Catanese MT, Burton DR, Law M, Rice CM, Ploss A. A genetically humanized mouse model for hepatitis C virus infection. Nature. 2011 474:208-11. PMCID: PMC3159410.


Li Y, O’Dell S, Walker LM, Wu X, Guenaga J, Feng Y, Schmidt SD, McKee K, Louder MK, Ledgerwood JE, Graham BS, Haynes BF, Burton DR, Wyatt RT, Mascola JR. Mechanism of neutralization by the broadly neutralizing HIV-1 monoclonal antibody VRC01. J Virol. 2011 85:8954-67. PMCID: PMC3165784.


Pejchal R, Doores KJ, Walker LM, Khayat R, Huang PS, Wang SK, Stanfield RL, Julien JP, Ramos A, Crispin M, Depetris R, Katpally U, Marozsan A, Cupo A, Maloveste S, Liu Y, McBride R, Ito Y, Sanders RW, Ogohara C, Paulson JC, Feizi T, Scanlan CN, Wong CH, Moore JP, Olson WC, Ward AB, Poignard P, Schief WR, Burton DR*, Wilson IA*. A potent and broad neutralizing antibody recognizes and penetrates the HIV glycan shield. Science. 2011 334:1097-103. PMCID: PMC3280215.


Weinfurter JT, May GE, Soma T, Hessell AJ, León EJ, Macnair CE, Piaskowski SM, Weisgrau K, Furlott J, Maness NJ, Reed J, Wilson NA, Rakasz EG, Burton DR, Friedrich TC. Macaque long-term nonprogressors resist superinfection with multiple CD8+ T cell escape variants of simian immunodeficiency virus. J Virol. 2011 85:530-41. PMCID: PMC3014170.


Scheid JF, Hugo M, Ueberheide B, Diskin R, Klein F, Olivera TYK, Pietzsch J, Fenyo D, Abadir A, Velinzon K,  Hurley A,  Myung S,  Boulad F,  Poignard P, Burton DR,  Pereyra F,  Ho DD, Walker BD, Seaman MS, Bjorkman PJ, Chait BT, Nussenzweig MC. Sequence and Structural Convergence of Broad and Potent HIV Antibodies That Mimic CD4 Binding. Science 2011 333:1633-7. PMCID: PMC3351836.


Burton DR*, Hessell AJ, Keele BF, Klasse PJ, Ketas TA, Moldt B, Dunlop DC, Poignard P, Doyle LA, Cavacini L, Veazey RS, Moore JP*.  Limited or no protection by weakly or nonneutralizing antibodies against vaginal SHIV challenge of macaques compared with a strongly neutralizing antibody. Proc Natl Acad Sci. 2011 108:11181-6. PMCID: PMC3131343.


Walker LM, Huber M, Doores KJ, Falkowska E, Pejchal R, Julien JP, Wang SK, Ramos A, Chan-Hui PY, Moyle M, Mitcham JL, Hammond PW, Olsen OA, Phung P, Fling S, Wong CH, Phogat S, Wrin T, Simek MD, Protocol G Principal Investigators, Koff WC, Wilson IA, Burton DR*, Poignard P*. Broad neutralization coverage of HIV by multiple highly potent antibodies. Nature. 2011 477:466-70. PMCID: PMC339310.

Walker LM, Sok D, Nishimura Y, Pejchal R, Ramos A, Simek MD, Geng Y, Wilson IA, Poignard P, Martin MA*, Burton DR*. Rapid development of glycan-specific, broad and potent anti-HIV-1 gp120 neutralizing antibodies in a SHIV- infected macaque Proc Natl Acad Sci. 2011 108(50):20125-9. PMCID: PMC 3250170.


Wu X, Zhou T, Zhu J, Zhang B, Georgiev I, Wang C, Chen X, Longo NS, Louder M, McKee K, O’Dell S, Perfetto S, Schmidt SD, Shi W, Wu L, Yang Y, Yang ZY, Yang Z, Zhang Z, Bonsignori M, Crump JA, Kapiga SH, Sam N.E, Haynes BF, Simek M, Burton DR, Koff WC, Doria-Rose NA, Connors M, NISC Comparative Sequencing Program, Mullikin JC, Nabel GJ, Roederer M, Shapiro L, Kwong PD, Mascola JR. Focused evolution of HIV-1 neutralizing antibodies revealed by structures and deep sequencing. Science. 2011 333:1593-602. PMCID: PMC Journal.


McLellan JS, M Pancera M, Carrico C, Gorman J, Julien JP, Khayat R, Louder R, Pejchal R, Sastry M, Dai K, O’Dell S, Patel N, Shahzad-Ul-Hussan S, Yang Y, Zhang B, Zhou T, Zhu J, Boyington JC, Chuang GY, Diwanji D, Georgiev I, Do Kwon Y, Lee D, Louder MK, Moquin S, Schmidt SD, Yang ZY, Bonsignori M, Crump JA, Kapiga SH, Sam NE, Haynes BF, Burton DR, Koff WC, Walker LM, Phogat S, Wyatt R, Orwenyo JWang LX, Arthos J, Bewley CA, Mascola JR, Nabel GJ, Schief WR, Ward AB, Wilson IA, Kwong PD. Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9. Nature. 480(7377):336-43. 2011 PMCID: PMC3406929.


Wahl-Jensen V, Kurz S, Feldmann F, Buehler LK, Kindrachuk J, DeFilippis V, da Silva Correia J, Früh K, Kuhn JH, Burton DR, Feldmann H. Ebola virion attachment and entry into human macrophages profoundly effects early cellular gene expression. PLoS Negl Trop Dis. 2011 5:e1359. PMID: PMC3196478.


Ahmed FK, Clark BE, Burton DR, Pantophlet R. An engineered mutant of HIV-1 gp120 formulated with adjuvant Quil A promotes elicitation of antibody responses overlapping the CD4-binding site. Vaccine. 2012 30(5):922-30.


Montero M, Gulzar N, Klaric KA, Donald JE, Lepik C, Wu S, Tsai S, Julien JP, Hessell AJ, Wang S, Lu S, Burton DR, Pai EF, Degrado WF, Scott JK. Neutralizing epitopes in the membrane-proximal external region of HIV-1 gp41 are influenced by the transmembrane domain and the plasma membrane. J Virol. 2012 86(6):2930-41. PMCID: PMC3302331.


Falkowska E, Ramos A, Feng Y, Zhou T, Moquin S, Walker LM, Wu X, Seaman MS, Wrin T, Kwong PD, Wyatt RT, Mascola JR, Poignard P, Burton DR. PGV04, an HIV-1 gp120 CD4 binding site antibody, is broad and potent in neutralization but does not induce conformational changes characteristic of CD4. J Virol. 2012 86(8):4394-403.PMCID: PMC3318667.


Moldt B, Shibata-Koyama M, Rakasz EG, Schultz N, Kanda Y, Dunlop DC, Finstad SL, Jin C, Landucci G, Alpert MD, Dugast AS, Parren PW, Nimmerjahn F, Evans DT, Alter G, Forthal DN, Schmitz JE, Iida S, Poignard P, Watkins DI, Hessell AJ, Burton DR. A nonfucosylated variant of the anti-HIV-1 monoclonal antibody b12 has enhanced FcγRIIIa-mediated antiviral activity in vitro but does not improve protection against mucosal SHIV challenge in macaques. J Virol. 2012 86(11):6189-96. PMCID: PMC3372207.


Giang E, Dorner M, Prentoe JC, Dreux M, Evans MJ, Bukh J, Rice CM, Ploss A, Burton DR, Law M. Human broadly neutralizing antibodies to the envelope glycoprotein complex of hepatitis C virus. Proc Natl Acad Sci U S A. 2012 109(16):6205-10. PMCID: PMC3341081.


Kong L, Giang E, Robbins JB, Stanfield RL, Burton DR, Wilson IA, Law M. Structural basis of hepatitis C virus neutralization by broadly neutralizing antibody HCV1.Proc Natl Acad Sci U S A. 2012 109(24):9499-504. PCMID: PMC3386053.


Doria-Rose NA, Georgiev I, O’Dell S, Chuang GY, Staupe RP, McLellan JS, Gorman J, Pancera M, Bonsignori M, Haynes BF, Burton DR, Koff WC, Kwong PD, Mascola JR. A short segment of the HIV-1 gp120 V1/V2 region is a major determinant of resistance to V1/V2 neutralizing antibodies. J Virol. 2012 86(15):8319-23. PMCID: PMC3421697.


Burton DR, Poignard P, Stanfield RL, Wilson IA. Broadly neutralizing antibodies present new prospects to counter highly antigenically diverse viruses. Science. 2012 337(6091):183-6. Review.


Poignard P, Moldt B, Maloveste K, Campos N, Olson WC, Rakasz E, Watkins DI, Burton DR. Protection against high-dose highly pathogenic mucosal SIV challenge at very low serum neutralizing titers of the antibody-like molecule CD4-IgG2. PLoS One. 2012 7(7):e42209. PCMID: PMC3407103.


Zhu J, O’Dell S, Ofek G, Pancera M, Wu X, Zhang B, Zhang Z; NISC Comparative Sequencing Program, Mullikin JC, Simek M, Burton DR, Koff WC, Shapiro L, Mascola JR, Kwong PD. Somatic Populations of PGT135-137 HIV-1-Neutralizing Antibodies Identified by 454 Pyrosequencing and Bioinformatics. Front Microbiol. 2012 3:315. PMCID: PMC3441199.


Ota T, Doyle-Cooper C, Cooper AB, Huber M, Falkowska E, Doores KJ, Hangartner L, Le K, Sok D, Jardine J, Lifson J, Wu X, Mascola JR, Poignard P, Binley JM, Chakrabarti BK, Schief WR, Wyatt RT, Burton DR, Nemazee D. Anti-HIV B Cell Lines as Candidate Vaccine Biosensors. J Immunol. 2012 189(10):4816-24.


Murphy MF, Lilley F, Lalor MJ, Crosby SR, Madden G, Johnston G, Burton DR. Evaluation of a nonlinear Hertzian-based model reveals prostate cancer cells respond differently to force than normal prostate cells. Microsc Res Tech. 2012 Oct 16. doi: 10.1002/jemt.22132. [Epub ahead of print].


Burton DR, Ahmed R, Barouch DH, Butera ST, Crotty S, Godzik A, Kaufmann DE, McElrath MJ, Nussenzweig MC, Pulendran B, Scanlan CN, Schief WR, Silvestri G, Streeck H, Walker BD, Walker LM, Ward AB, Wilson IA, Wyatt R. A Blueprint for HIV Vaccine Discovery. Cell Host Microbe. 2012 12(4):396-407. PMCID: NIHSM413009.


Moldt B, Rakasz EG, Schultz N, Chan-Hui PY, Swiderek K, Weisgrau KL, Piaskowski SM, Bergman Z, Watkins DI, Poignard P, Burton DR. Highly potent HIV-specific antibody neutralization in vitro translates into effective protection against mucosal SHIV challenge in vivo. Proc Natl Acad Sci U S A. 2012 109(46):18921-5.


Benhnia MR, Maybeno M, Blum D, Aguilar-Sino R, Matho M, Meng X, Head S, Felgner PL, Zajonc DM, Koriazova L, Kato S, Burton DR, Xiang Y, Crowe JE Jr, Peters B, Crotty S. Unusual features of vaccinia virus extracellular virion form (EV) neutralization resistance revealed in human antibody responses to the smallpox vaccine. J Virol. 2012 Nov 14.


Hoot S, McGuire AT, Cohen KW, Strong RK, Hangartner L, Klein F, Diskin R, Scheid JF, Sather DN, Burton DR, Stamatatos L. 2013. Recombinant HIV envelope proteins fail to engage germline versions of anti-CD4bs bNAbs. PLoS Pathog 9, e1003106.


Doores KJ, Huber M, Le KM, Wang SK, Doyle-Cooper C, Cooper A, Pantophlet R, Wong CH, Nemazee D, Burton DR. 2G12-expressing B cell lines inform HIV carbohydrate vaccine design strategies. J Virol. 2013 87:2234-41.